New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
07:47 EDTJNJ, CGJNJ accepts $4B binding offer from Carlyle to acquire Ortho-Clinical Diagnostics
Johnson & Johnson (JNJ) announced that it has accepted the binding offer from Carlyle Group (CG), which was received and announced on January 16, 2014, to acquire its Ortho-Clinical Diagnostics business for approximately $4B, subject to customary adjustments. This acceptance was made after consultation with the relevant works councils and trade unions. The transaction is expected to close toward the middle of the year, upon satisfaction of customary closing conditions. :theflyonthe
News For JNJ;CG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 28, 2014
15:44 EDTCGNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Southern Company (SO), consensus $1.07; Phillips 66 (PSX), consensus $1.75; Automatic Data Processing (ADP), consensus 60c; Praxair (PX), consensus $1.63; WellPoint (WLP), consensus $2.27; Exelon (EXC), consensus 73c; Eaton (ETN), consensus $1.23; Hess (HES), consensus $1.08; TE Connectivity (TEL), consensus $1.00; McGraw Hill Financial (MHFI), consensus 94c; Waste Management (WM), consensus 68c; Hershey (HSY), consensus $1.08; Ralph Lauren (RL), consensus $2.06; Wisconsin Energy (WEC), consensus 53c; Garmin (GRMN), consensus 71c; Sealed Air (SEE), consensus 46c; DENTSPLY (XRAY), consensus 60c; Goodyear Tire (GT), consensus 70c; Revlon (REV), one estimate 45c; Booz Allen (BAH), consensus 41c; Carlyle Group (CG), consensus 54c.
13:09 EDTJNJOptions with increasing implied volatility
Subscribe for More Information
07:22 EDTCGNYSSA to hold a conference
Subscribe for More Information
07:21 EDTJNJCBI to hold a conference
Subscribe for More Information
07:20 EDTCGTechAmerica Foundation to hold a conference
Subscribe for More Information
October 27, 2014
07:29 EDTJNJWorldwide Business Research to hold a conference
ProcureCon Pharma 2014 is being held in Philadelphia on October 27-29.
October 24, 2014
08:15 EDTJNJJohnson & Johnson management to meet with JPMorgan
Meetings to be held in Chicago/Kansas City on October 29 hosted by JPMorgan.
06:32 EDTJNJJohnson & Johnson found 'not liable' in all-metal hip implant suit, WSJ reports
Subscribe for More Information
October 23, 2014
06:16 EDTCGPetSmart attracts interest from KKR, NY Post reports
Subscribe for More Information
05:58 EDTJNJStocks with implied volatility below IV index mean; XLNX JNJ
Subscribe for More Information
October 22, 2014
17:50 EDTJNJBavarian Nordic announces expanded collaboration with Janssen on MVA-BN
Bavarian Nordic A/S announced that it has agreed with Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), to expand the collaboration announced earlier to include evaluation of Bavarian Nordic's proprietary vaccine platform technology, MVA-BN, for additional undisclosed disease targets. Bavarian Nordic and Janssen will collaborate on the evaluation of MVA-BN for three additional infectious disease targets. Janssen is granted the exclusive option to collaborate on one or more of the targets, following scientific evaluation of MVA-BN-based vaccine candidates, which will be developed by Bavarian Nordic.
13:37 EDTCGPE firms may bid on Bayer's MaterialScience unit, Reuters says
Subscribe for More Information
05:31 EDTJNJJohnson & Johnson announces commitment to speed Ebola vaccine development
Subscribe for More Information
October 20, 2014
12:36 EDTJNJOptions with decreasing implied volatility
Subscribe for More Information
08:14 EDTJNJPharmacyclics files supplmeental NDA for Imbruvica for macroglobulinemia
Pharmacyclics (PCYC) announced that it has submitted a supplemental New Drug Application to the FDA based on data from a Phase 2 study evaluating the use of IMBRUVICA in patients with Waldenstrom's macroglobulinemia. IMBRUVICA, which received FDA Breakthrough Therapy Designation in February 2013 for patients with WM, is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech (JNJ).
October 17, 2014
16:55 EDTJNJStocks end volatile week lower amid oil price plunge
Subscribe for More Information
10:37 EDTJNJOptions with decreasing implied volatility: ATLS JNJ XLNX JNK HYG
Subscribe for More Information
08:57 EDTJNJPharmacyclics price target raised to $188 from $185 at Roth Capital
Subscribe for More Information
08:51 EDTJNJPharmacyclics announces European approval for Imbruvica
Subscribe for More Information
08:02 EDTJNJCovidien granted preliminary injunction against Ethicon's Harmonic ACE+7
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use